Literature DB >> 17626164

Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus.

Mads Lerdrup1, Silas Bruun, Michael V Grandal, Kirstine Roepstorff, Malene M Kristensen, Anette M Hommelgaard, Bo van Deurs.   

Abstract

High ErbB2 levels are associated with cancer, and impaired endocytosis of ErbB2 could contribute to its overexpression. Therefore, knowledge about the mechanisms underlying endocytic down-regulation of ErbB2 is warranted. The C-terminus of ErbB2 can be cleaved after various stimuli, and after inhibition of HSP90 with geldanamycin this cleavage is accompanied by proteasome-dependent endocytosis of ErbB2. However, it is unknown whether C-terminal cleavage is linked to endocytosis. To study ErbB2 cleavage and endocytic trafficking, we fused yellow fluorescent protein (YFP) and cyan fluorescent protein (CFP) to the N- and C-terminus of ErbB2, respectively (YFP-ErbB2-CFP). After geldanamycin stimulation YFP-ErbB2-CFP became cleaved in nonapoptotic cells in a proteasome-dependent manner, and a markedly larger relative amount of cleaved YFP-ErbB2-CFP was observed in early endosomes than in the plasma membrane. Furthermore, cleavage took place at the plasma membrane, and cleaved ErbB2 was internalized and degraded far more efficiently than full-length ErbB2. Concordantly, a C-terminally truncated ErbB2 was also readily endocytosed and degraded in lysosomes compared with full-length ErbB2. Altogether, we suggest that geldanamycin leads to C-terminal cleavage of ErbB2, which releases the receptor from a retention mechanism and causes endocytosis and lysosomal degradation of ErbB2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17626164      PMCID: PMC1951740          DOI: 10.1091/mbc.e07-01-0025

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  49 in total

Review 1.  c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients.

Authors:  S De Placido; C Carlomagno; M De Laurentiis; A R Bianco
Journal:  Breast Cancer Res Treat       Date:  1998       Impact factor: 4.872

2.  Inhibition of the vacuolar H(+)-ATPase with bafilomycin reduces delivery of internalized molecules from mature multivesicular endosomes to lysosomes in HEp-2 cells.

Authors:  B van Deurs; P K Holm; K Sandvig
Journal:  Eur J Cell Biol       Date:  1996-04       Impact factor: 4.492

Review 3.  The role of APP processing and trafficking pathways in the formation of amyloid beta-protein.

Authors:  D J Selkoe; T Yamazaki; M Citron; M B Podlisny; E H Koo; D B Teplow; C Haass
Journal:  Ann N Y Acad Sci       Date:  1996-01-17       Impact factor: 5.691

4.  Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers.

Authors:  S K Muthuswamy; M Gilman; J S Brugge
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

5.  ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors.

Authors:  R Worthylake; L K Opresko; H S Wiley
Journal:  J Biol Chem       Date:  1999-03-26       Impact factor: 5.157

6.  Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu.

Authors:  R L Hong; W H Spohn; M C Hung
Journal:  Clin Cancer Res       Date:  1999-07       Impact factor: 12.531

7.  Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation.

Authors:  Z Wang; L Zhang; T K Yeung; X Chen
Journal:  Mol Biol Cell       Date:  1999-05       Impact factor: 4.138

Review 8.  HER-2/neu as a predictive marker of response to breast cancer therapy.

Authors:  M D Pegram; G Pauletti; D J Slamon
Journal:  Breast Cancer Res Treat       Date:  1998       Impact factor: 4.872

Review 9.  The biology of erbB-2/neu/HER-2 and its role in cancer.

Authors:  N E Hynes; D F Stern
Journal:  Biochim Biophys Acta       Date:  1994-12-30

10.  Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin.

Authors:  E G Mimnaugh; C Chavany; L Neckers
Journal:  J Biol Chem       Date:  1996-09-13       Impact factor: 5.157

View more
  26 in total

1.  ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination.

Authors:  Corina Marx; Jason M Held; Bradford W Gibson; Christopher C Benz
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

2.  Geldanamycin selectively targets the nascent form of ERBB3 for degradation.

Authors:  Candice S Gerbin; Ralf Landgraf
Journal:  Cell Stress Chaperones       Date:  2010-01-19       Impact factor: 3.667

3.  Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells.

Authors:  Daniel J Barr; Anne G Ostermeyer-Fay; Rachel A Matundan; Deborah A Brown
Journal:  J Cell Sci       Date:  2008-09-02       Impact factor: 5.285

4.  A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells.

Authors:  Srikumar M Raja; Robert J Clubb; Mitra Bhattacharyya; Manjari Dimri; Hao Cheng; Wei Pan; Cesar Ortega-Cava; Alagarsamy Lakku-Reddi; Mayumi Naramura; Vimla Band; Hamid Band
Journal:  Cancer Biol Ther       Date:  2008-10-09       Impact factor: 4.742

Review 5.  Endocytosis and intracellular trafficking of ErbBs.

Authors:  Alexander Sorkin; Lai Kuan Goh
Journal:  Exp Cell Res       Date:  2008-08-28       Impact factor: 3.905

6.  Role of Erbin in ErbB2-dependent breast tumor growth.

Authors:  Yanmei Tao; Chengyong Shen; Shiwen Luo; Wilfried Traoré; Sylvie Marchetto; Marie-Josée Santoni; Linlin Xu; Biao Wu; Chao Shi; Jinghong Mei; Ryan Bates; Xihui Liu; Kai Zhao; Wen-Cheng Xiong; Jean-Paul Borg; Lin Mei
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-06       Impact factor: 11.205

7.  Septin oligomerization regulates persistent expression of ErbB2/HER2 in gastric cancer cells.

Authors:  Elizabeth A Marcus; Elmira Tokhtaeva; Shahlo Turdikulova; Joseph Capri; Julian P Whitelegge; David R Scott; George Sachs; Fedor Berditchevski; Olga Vagin
Journal:  Biochem J       Date:  2016-04-05       Impact factor: 3.857

8.  A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells.

Authors:  Tameka A Bailey; Haitao Luan; Eric Tom; Timothy Alan Bielecki; Bhopal Mohapatra; Gulzar Ahmad; Manju George; David L Kelly; Amarnath Natarajan; Srikumar M Raja; Vimla Band; Hamid Band
Journal:  J Biol Chem       Date:  2014-09-15       Impact factor: 5.157

9.  A heat-shock protein axis regulates VEGFR2 proteolysis, blood vessel development and repair.

Authors:  Alexander F Bruns; Nadira Yuldasheva; Antony M Latham; Leyuan Bao; Caroline Pellet-Many; Paul Frankel; Sam L Stephen; Gareth J Howell; Stephen B Wheatcroft; Mark T Kearney; Ian C Zachary; Sreenivasan Ponnambalam
Journal:  PLoS One       Date:  2012-11-06       Impact factor: 3.240

10.  Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network.

Authors:  Inka Regine Weingaertner; Sarah Koutnik; Hermann Ammer
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.